BSND

From Wikipedia, the free encyclopedia

Template:Short description Template:Cs1 config An Error has occurred retrieving Wikidata item for infobox Bartter syndrome, infantile, with sensorineural deafness (Barttin), also known as BSND, is a human gene which is associated with Bartter syndrome.[1]

This gene encodes an essential beta subunit for CLC chloride channels. These heteromeric channels localize to basolateral membranes of renal tubules in the kidney and of potassium-secreting epithelia of the inner ear. Mutations in this gene have been associated with Bartter syndrome with sensorineural deafness.[1]

As a diagnostic marker

BSND is a key diagnostic marker in differentiating the chromophobe renal cell carcinoma (chRCC) from other types of RCC. chRCC is a type of kidney cancer that presents in the cell lining of the small tubules in the kidney.[2] RNA-sequence data from The Cancer Genome Atlas revealed that BSND was one of three genes (alongside ATP6V1G3) with high RNA expression in chRCC. Strong, diffuse expression of BSND was observed in chRCC but not in clear cell RCC or papillary RCC. Additionally, BSND expression was found to correlate with lower DNA methylation near the transcription start site, indicating the presence of epigenetic regulation. This expression reveals BSND's potential to serve as a major immunohistochemical marker for distinguishing chRCC from other forms of RCC.[3]

BSND immunohistochemistry is also pivotal in differentiating oncocytic and Warthin-like MECs in salivary gland neoplasms. Greater than 10% BSND positivity helps distinguish Warthin tumors from Warthin-like MECs and greater than 20% BSND positivity helps distinguish oncocytomas from oncocytic MECs.[4]

References

Page Template:Reflist/styles.css has no content.

  1. ^ a b Page Module:Citation/CS1/styles.css has no content."BSND barttin CLCNK type accessory subunit beta [ Homo sapiens (human) ]".
  2. ^ Page Module:Citation/CS1/styles.css has no content.Meskawi M, Sun M, Ismail S, Bianchi M, Hansen J, Tian Z, Hanna N, Trinh QD, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI (August 2013). "Fuhrman grade [corrected] has no added value in prediction of mortality after partial or [corrected] radical nephrectomy for chromophobe renal cell carcinoma patients". Modern Pathology. 26 (8): 1144–1149. doi:10.1038/modpathol.2012.230. PMID 23370773.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  3. ^ Page Module:Citation/CS1/styles.css has no content.Shinmura K, Igarashi H, Kato H, Koda K, Ogawa H, Takahashi S, et al. (Jun 19, 2015). "BSND and ATP6V1G3: Novel Immunohistochemical Markers for Chromophobe Renal Cell Carcinoma". Medicine (Baltimore). 94 (24): e989. doi:10.1097/MD.0000000000000989. PMC 4616546. PMID 26091477 – via PubMed Central.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Xu B, Jungbluth A, Frosina D, Alabkaa A, Serrette R, Qin H, et al. (November 26, 2024). "The Utility of BSND Immunohistochemistry in the Differential Diagnosis of Oncocytic and Warthin-like Mucoepidermoid Carcinoma of Salivary Gland". Head and Neck Pathology. 18 (123) 123. doi:10.1007/s12105-024-01728-0. PMC 11599517. PMID 39589616 – via Springer Nature.

Further reading

Page Template:Refbegin/styles.css has no content.

Template:Asbox Template:Asbox